Recent

% | $
Quotes you view appear here for quick access.

Opko Health, Inc. Message Board

  • vix1830 vix1830 Feb 21, 2014 9:57 AM Flag

    Value Walk $11 Opko Health Inc. (OPK): Diagnostic Pipeline,

    Opko Health Inc. (OPK): Diagnostic Pipeline, Therapeutic Platforms Exciting
    by VW StaffFebruary 21, 2014, 7:30 am
    Barrington Research analyst Charley R. Jones reiterate an Outperform rating for Opko Health Inc. (NYSE:OPK) as the Claros and Peptoid diagnostic platforms provide an enticing opportunity for the company.
    Opko Health completes the calibration confirmation of its 4KscoreTM algorithm
    On Thursday, February 13, Opko Health Inc. (NYSE:OPK) announced the successful completion of the calibration confirmation of its 4KscoreTM algorithm validation study currently underway at 21 urology clinics. We had a chance to meet with the new head, Dr. David Okrongly, Ph.D., of Opko Health ’s diagnostics division recently and we came away feeling very confident about each of OPK’s diagnostic programs. In addition, we came away knowing that Opko Health now has the right person running that division. We believe his background and experience, such as running Siemens molecular diagnostics division, is a perfect fit, because of his large company experience, which we believe will be important for Opko Health as we expect revenues to be far greater than $1 billion eventually. He will also be vital in evaluating new technologies which will be important for Opko Health’s future.
    We were first attracted to Opko Health Inc. (NYSE:OPK) because of the Claros and Peptoid diagnostic platforms out of Scripps, but we always recognized that the 4Kscore could have a $500 million potential if the urology community is open to change. We believe it should be and we also believe 4kScore is a great start to getting the best treatment of this disease on track. The confirmation of the 4Kscore algorithm should provide investors some confidence that the investments Opko Health has been making are beginning to ripen. In the case of peptoids, there is unlikely to be an Alzheimer’s test by 2017, however, our confidence that this platform will be vital for a number of autoimmune related diseases remains v

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OPK
16.25-0.02(-0.12%)Jul 2 4:03 PMEDT